Dr. Bruce L. Booth

Biography

  Dr. Bruce L. Booth, Ph.D., D.Phil. serves as a Partner of Atlas Venture L.P. and Atlas Venture Fund XI, L.P. Dr. Booth joined Atlas Venture L.P. in 2005 served as its Managing Director. He focuses on Life Sciences, Novel Biopharmaceutical Products, Therapeutic Platforms and Innovative Biomedical Technologies. Dr. Booth blogs about biotech and venture capital topics at LifeSciVC.com. He is Co-Founder and Chairman of Kymera Therapeutics LLC. He served as an Acting Chief Executive Officer of Rodin Therapeutics Inc. until October 6, 2015 which he co-founded. Dr. Booth served as a Principal and Investor at Caxton Health Holdings LLC and focused on its private equity activities, ranging from early stage venture capital through late stage buyouts. Prior to Caxton Health, he was an Associate Principal and Consultant at McKinsey & Company, Inc., where Dr. Booth focused on research and development productivity, corporate strategy and business development issues for major biopharmaceutical companies and helped to build the Pharma R&D practice. While at Mckinsey, he also co-led its international scholars recruiting efforts. He seeded and incubated Zafgen and identified and facilitated the successful in-licensing of the lead drug program. He co-founded Nimbus Discovery, LLC. in 2009. He co-founded Nimbus Therapeutics, Inc., in 2009 and served as acting Chief Executive Officer of Nimbus while incubated at Atlas Venture's offices. Dr. Booth co-founded miRagen Therapeutics, Inc. in 2006. He has been the Chairman of the Board of Directors of miRagen Therapeutics, Inc. since September 2007. He serves as Treasurer of New York Academy Of Medicine. He serves as the Chairman of AvroBio, Rodin Therapeutics Inc. Dr. Booth serves as the Chairman of Quartet Medicine, Inc. He served as Chairman of Padlock Therapeutics, Inc. He served as Chairman of Nimbus Therapeutics, Inc. until November 1, 2012 and serves as its Director. He has been an Independent Director of Zafgen, Inc. since August 2006. He has been a Director at Numerate, Inc. since June 24, 2014, Magenta Therapeutics and Lysosomal Therapeutics, Inc. since May 12, 2014. He serves as a Director of Unum Therapeutics Inc. He serves as a Director at Magenta Therapeutics, Inc. He serves as Director of Nimbus Discovery, LLC. He serves as a Member of Accelerating Bench to Bedside effort at Beth Israel Deaconess Medical Center, Inc. He also serves on the Center for Medicine in the Public Interest. He serves as a Member of Scientific Advisory Board at UCB Pharma S.A., Shire, Takeda as well as Pfizer's Healthcare "R&D 2020" Innovation Think Tank and participates on several other advisory boards for academic medical centers. He serves as a Member of the Board of Directors of AVROBIO Inc. Dr. Booth serves on the New York Academy of Medicine Board of Trustees, where he helps manage the Academy's Endowment. He is a Board member of National Venture Capital Association. He served as a Director of Bicycle Therapeutics Limited until September 03, 2015 and Padlock Therapeutics, Inc. He served as Director at Nxstage Medical, Inc., since July 2005. He served on the Board of Prestwick, Celgene Avilomics Research, Inc. (Avila), Stromedix, Inc., and Proprius. Prior to graduate studies, he worked on President Clinton's Domestic Policy Council in the National Office of AIDS policy. He served as a Board Observer of Bicycle Therapeutics Limited since September 03, 2015. He served as a Junior Dean of Trinity College. He joined the Science Exchange's Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research. He served as Member of the Supervisory Board at ProtAffin Biotechnologie AG. He served as Chairman of the Board and Director at On-Q-ity Inc. He served as a Director of Ivrea Pharmaceuticals, Inc. He served as Chairman of Nimbus Discovery, LLC until November 1, 2012. He is instrumental in forming unique, innovative and capital efficient structures for drug discovery and development. Dr. Booth has also authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery. In 2010, he was named to Boston Business Journal's "40 under 40" list. In his research at Oxford, he also received the Overseas Research Fellowship. His work focused on the study of HIV and tumor immune responses. Dr. Booth earned a Doctorate in Molecular Immunology from the Oxford University's Nuffield Department of Medicine and Weatherall Institute of Molecular Medicine, as a British Marshall Scholar. Dr. Booth received a D.Phil. (Ph.D.) in Molecular Immunology from Oxford University, B.Sc. degree summa cum laude in Biochemistry from the Pennsylvania State University, where Dr. Booth was an Evan Pugh Scholar.

Research Interest

Life Sciences, Novel Biopharmaceutical